But three of those FDA employees told CNN that Elsa just makes up nonexistent studies, something commonly referred to in AI ...

Insiders tell CNN the FDA’s AI is “hallucinating” studies and can’t access key documents. Agency leaders insist the AI is getting better, and use is not mandatory.

Insiders at the Food and Drug Administration are ringing alarm bells over the agency's use of an AI to fast-track drug ...

The federal agency introduced Elsa last month, boasting about the AI tool's ability to increase efficiency at the FDA.

FDA officials say the assistant is flawed, just as the Trump administration stresses AI adoption in healthcare.

The FDA's generative AI, Elsa, has a massive hallucination problem, according to the agency's employees themselves.

In recent years, Artificial Intelligence (AI) has made significant strides across various sectors, providing innovative solutions and enhancing efficiency. However, ...

Despite ambitions to streamline regulatory review, FDA’s Elsa platform has been prone to hallucinations, prompting internal scrutiny and questions about AI reliability and governance.

With reports that FDA’s AI Elsa is “confidently hallucinating” studies that don’t exist, the use of AI to streamline drug review and speed up approval is not here yet.

U.S. Food and Drug Administration employees told CNN that Elsa — the AI model that’s supposed to help speed up approvals of pharmaceuticals and medical devices — isn’t working great. Instead, it cites ...

"Elsa" is supposed to speed up the process of approving drugs and medical devices. But FDA employees say the AI is creating ...

AI is transforming healthcare, from interpreting scans to powering early warning systems that guide diagnosis and treatment.